Cited by 1,280Cancer-related Molecular PathwaysDevelopmental Biology and Gene RegulationCell death mechanisms and regulation

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53

Jones, Stephen N., Roe, Amy E., Donehower, Lawrence A., Bradley, Allan·1995·Nature

DOI 10.1038/378206a0

Open this paper in CoChat — free account

Abstract

The Mdm2 proto-oncogene was originally identified as one of several genes contained on a mouse double minute chromosome present in a transformed derivative of 3T3 cells. Overexpression of Mdm2 can immortalize primary cultures of rodent fibroblasts. Human MDM2 is amplified in 30-40% of sarcomas, and is overexpressed in leukaemic cells. The Mdm2 oncoprotein forms a complex with the p53 tumour-suppressor protein and inhibits p53-mediated transregulation of gene expression. Because Mdm2 expression increases in response to p53, Mdm2-p53 binding may autoregulate Mdm2 expression and modulate the activity of p53 in the cell. We have created Mdm2-null and Mdm2/p53-null mice to determine whether Mdm2 possesses developmental functions in addition to the ability to complex with p53, and to investigate the biological role of Mdm2-p53 complex formation in development. Mice deficient for Mdm2 die early in development. In contrast, mice deficient for both Mdm2 and p53 develop normally and are viable. These results suggest that a critical role of Mdm2 in development is the regulation of p53 function.

Integrity signals

Registry

Crossref · 10.1038/378206a0

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Self-citation
Participation of p53 protein in the cellular response to DNA damage.
Kastan, M. B., Onyekwere, O. C., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991) · PubMed · Cited by 3,761
The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Amplification of a gene encoding a p53-associated protein in human sarcomas
Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949
The p53-mdm-2 autoregulatory feedback loop.
Wu, X., Bayle, J. H., Olson, D., & Levine, A. J. (1993) · Genes & Development · doi:10.1101/gad.7.7a.1126 · Cited by 1,801
The Atlas of Mouse Development
Kaufman, M. H. (1992) · Medical Entomology and Zoology · Cited by 1,750
Disruption of the proto-oncogene int-2 in mouse embryo-derived stem cells: A general strategy for targeting mutations to non-selectable genes
Mansour, S. L., Thomas, K. R., & Capecchi, M. R. (1988) · Nature · doi:10.1038/336348a0 · Cited by 1,683
The atlas of mouse development
Beddington, R. S. P. (1993) · Trends in Genetics · doi:10.1016/0168-9525(93)90071-o · Cited by 1,416
α-lnhibin is a tumour-suppressor gene with gonadal specificity in mice
Matzuk, M. M., Finegold, M. J., Su, J.-G. J., Hsueh, A. J. W., & Bradley, A. (1992) · Nature · doi:10.1038/360313a0 · Cited by 893
Self-citation

Flagged first, then by citations

Show all 24 references

Research works printed but not linked: 5

Juven, T., Barak, Y., Zauberman, A., George, D. & Oren, M. Oncogene 8, 3411–3416 (1993).
Snow, M. H. L. J. Embryol. exp. Morph. 42, 293–303 (1977).
Baker, S. J., Markowitz, S., Fearon, E. R., Willson, J. K. V. & Vogelstein, B. Science 253, 49–53 (1990).
Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B. & Craig, R. W. Cancer Res. 51, 6304–6311 (1991).
Olson, D. C. et al. Oncogene 8, 2353–2360 (1993).

Sorted by citations

Items 401–500 of 1,000

Increased Radioresistance and Accelerated B Cell Lymphomas in Mice with Mdmx Mutations that Prevent Modifications by DNA-Damage-Activated Kinases
Wang, Y. V., Leblanc, M., Wade, M., Jochemsen, A. G., & Wahl, G. M. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.05.008 · Cited by 79
“Mice lacking either Mdm2 or Mdmx die during embryogenesis, and the embryonic lethality is rescued by p53 deletion (Jones et al., 1995; Montes de Oca Luna et al., 1995; Parant et al., 2001; Migliorini et al., 2002).”
The role of p53 in developmental syndromes
Bowen, M. E., & Attardi, L. D. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjy087 · Cited by 78
Mechanisms Underlying Recurrent Genomic Amplification in Human Cancers
Tanaka, H., & Watanabe, T. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.02.019 · Cited by 79
Chapter 5 Sirtuins and p53
van Leeuwen, I., & Laı́n, S. (2009) · Advances in cancer research · doi:10.1016/s0065-230x(09)02005-3 · Cited by 82
Smad Ubiquitylation Regulatory Factor 1/2 (Smurf1/2) Promotes p53 Degradation by Stabilizing the E3 Ligase MDM2
Nie, J., Xie, P., Liu, L., Xing, G., Chang, Z., Yin, Y., Tian, C., He, F., & Zhang, L. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.126920 · Cited by 79
Deletion of p37Ing1 in Mice Reveals a p53-Independent Role for Ing1 in the Suppression of Cell Proliferation, Apoptosis, and Tumorigenesis
Coles, A. H., Liang, H., Zhu, Z., Marfella, C. G. A., Kang, J., Imbalzano, A. N., & Jones, S. N. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3558 · Cited by 79
Self-citation
Estrogen receptor protects p53 from deactivation by human double minute-2.
Liu, G., Schwartz, J. A., & Brooks, S. C. (2000) · PubMed · Cited by 79
Binding of p53 to the Central Domain of Mdm2 Is Regulated by Phosphorylation
Kulikov, R., Winter, M., & Blattner, C. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m513311200 · Cited by 79
Nerve growth factor receptor negates the tumor suppressor p53 as a feedback regulator
Zhou, X. Y., Hao, Q., Liao, P., Luo, S., Zhang, M., Hu, G., Liu, H., Zhang, Y.-W., Cao, B., Baddoo, M., et al. (2016) · eLife · doi:10.7554/elife.15099 · Cited by 84
MDM2 induces hyperplasia and premalignant lesions when expressed in the basal layer of the epidermis
Ganguli, G., Abecassis, J., & Wasylyk, B. (2000) · The EMBO Journal · doi:10.1093/emboj/19.19.5135 · Cited by 78
Interplay between the tumor suppressor p53 and TGFβ signaling shapes embryonic body axes inXenopus
Takebayashi‐Suzuki, K., Funami, J., Tokumori, D., Saito, A., Watabe, T., Miyazono, K., Kanda, A., & Suzuki, A. (2003) · Development · doi:10.1242/dev.00615 · Cited by 76
RFWD3–Mdm2 ubiquitin ligase complex positively regulates p53 stability in response to DNA damage
Fu, X., Yucer, N., Liu, S., Li, M., Yi, P., Mu, J.-J., Yang, T., Chu, J., Jung, S. Y., O’Malley, B. W., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912094107 · Cited by 73
A Direct Intersection between p53 and Transforming Growth Factor β Pathways Targets Chromatin Modification and Transcription Repression of the α-Fetoprotein Gene
Wilkinson, D. S., Ogden, S. K., Stratton, S. A., Piechan, J. L., Nguyen, T. T. T., Smulian, G. A., & Barton, M. C. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.3.1200-1212.2005 · Cited by 76
What have animal models taught us about the p53 pathway?
Lozano, G., & Zambetti, G. P. (2005) · The Journal of Pathology · doi:10.1002/path.1704 · Cited by 78
The regulation of MDM2 by multisite phosphorylation—opportunities for molecular-based intervention to target tumours?
Meek, D. W., & Hupp, T. R. (2010) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2009.10.005 · Cited by 76
Convergence of p53 and TGF-beta signaling networks
Dupont, S., Zacchigna, L., Adorno, M., Soligo, S., Volpin, D., Piccolo, S., & Cordenonsi, M. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.06.008 · Cited by 76
Use of a Retroinverso p53 Peptide as an Inhibitor of MDM2
Sakurai, K., Chung, H. S., & Kahne, D. E. (2004) · Journal of the American Chemical Society · doi:10.1021/ja044883w · Cited by 76
30 years and a long way into p53 research
Hainaut, P. L., & Wiman, K. G. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70198-6 · Cited by 80
A model of the onset of the senescence associated secretory phenotype after DNA damage induced senescence
Meyer, P., Maity, P., Burkovski, A., Schwab, J. D., Müssel, C., Singh, K., Ferreira, F. F., Krug, L., Maier, H. J., Wlaschek, M., et al. (2017) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005741 · Cited by 76
Ubiquitous Induction of p53 in Tumor Cells by Antisense Inhibition of MDM2 Expression
Chen, L., Lu, W., Agrawal, S., Zhou, W., Zhang, R., & Chen, J. (1999) · Molecular Medicine · doi:10.1007/bf03402136 · Cited by 73
DNA double-strand breaks: A potential causative factor for mammalian aging?
Li, H., Mitchell, J. R., & Hasty, P. (2008) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2008.02.002 · Cited by 76
Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population
Hu, Z., Ma, H., Li, J., Qian, J., Zhou, J.-N., Chen, Y., Xu, L., Wang, X., Wei, Q., & Shen, H. (2005) · International Journal of Cancer · doi:10.1002/ijc.21463 · Cited by 74
Essential Roles of E3 Ubiquitin Ligases in p53 Regulation
Sane, S., & Rezvani, K. S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020442 · Cited by 78
The p53 tumor suppressor: Critical regulator of life & death in cancer
Fisher, D. E. (2001) · APOPTOSIS · doi:10.1023/a:1009659708549 · Cited by 74
Spatio-temporal modelling of the Hes1 and p53-Mdm2 intracellular signalling pathways
Sturrock, M., Terry, A. J., Xirodimas, D. P., Thompson, A. M., & Chaplain, M. A. J. (2010) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2010.12.016 · Cited by 73
Switching mechanisms of cell death in mdm2- and mdm4-null mice by deletion of p53 downstream targets.
Chávez‐Reyes, A., Parant, J. M., Amelse, L. L., Luna, R. M. D. O., Korsmeyer, S. J., & Lozano, G. (2003) · PubMed · Cited by 73
Regulation of MDM2 E3 Ligase Activity by Phosphorylation after DNA Damage
Cheng, Q., Cross, B. L., Li, B., Chen, L., Li, Z., & Chen, J. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.05553-11 · Cited by 78
Structural analysis of MDM2 RING separates degradation from regulation of p53 transcription activity
Nomura, K., Klejnot, M., Kowalczyk, D., Hock, A. K., Sibbet, G. J., Vousden, K. H., & Huang, D. T. C. (2017) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3414 · Cited by 72
Targeting the MDM2-p53 protein–protein interaction for new cancer therapeutics
Wang, S., Zhao, Y., Bernard, D., Aguilar, A., & Kumar, S. (2012) · Topics in Medicinal Chemistry · doi:10.1007/978-3-642-28965-1_2 · Cited by 72
“The physiological relevance of this regulatory loop was demonstrated by the genetic evidence that embryonic lethality of Mdm2-null mice can be successfully rescued by the simultaneous deletion of the p53 gene [16, 17].”
Background
Hyperproliferation, cancer, and inflammation in mice expressing a Δ133p53-like isoform
Slatter, T. L., Hung, N. A., Campbell, H. G., Rubio, C., Mehta, R., Renshaw, P., Williams, G., Wilson, M., Engelmann, A., Jeffs, A. R., et al. (2011) · Blood · doi:10.1182/blood-2010-11-321851 · Cited by 76
Crystal Structures of Human MdmX (HdmX) in Complex with p53 Peptide Analogues Reveal Surprising Conformational Changes
Kallen, J. A., Goepfert, A., Blechschmidt, A., Izaac, A., Geiser, M., Tavares, G., Ramage, P., Furet, P., Masuya, K., & Lisztwan, J. H. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m809096200 · Cited by 75
DNA damage, p14ARF, Nucleophosmin (NPM/B23), and cancer
Gjerset, R. A. (2006) · Journal of Molecular Histology · doi:10.1007/s10735-006-9040-y · Cited by 71
Human Cytomegalovirus IE1-72 Activates Ataxia Telangiectasia Mutated Kinase and a p53/p21-Mediated Growth Arrest Response
Castillo, J., Frame, F. M., Rogoff, H. A., Pickering, M., Yurochko, A. D., & Kowalik, T. F. (2005) · Journal of Virology · doi:10.1128/jvi.79.17.11467-11475.2005 · Cited by 72
Regulation of the Mdm2–p53 pathway by the ubiquitin E3 ligase MARCH7
Zhao, K., Yang, Y., Zhang, G., Wang, C., Wang, D., Wu, M., & Mei, Y. (2018) · EMBO Reports · doi:10.15252/embr.201744465 · Cited by 70
p53: at the crossroad between cancer and ageing
Papazoglu, C., & Mills, A. (2007) · The Journal of Pathology · doi:10.1002/path.2086 · Cited by 75
Molecular pathology of primary and metastatic ductal pancreatic lesions
Ruggeri, B., Huang, L., Berger, D., Chang, H., Klein–Szanto, A. J., Goodrow, T. L., Wood, M., Obara, T., Heath, C. W., & Lynch, H. T. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970215)79:4 · Cited by 71
A novel small molecule inhibitor of MDM2-p53 (APG-115) enhances radiosensitivity of gastric adenocarcinoma
Yi, H., Yan, X., Luo, Q., Yuan, L., Li, B., Pan, W., Zhang, L., Chen, H., Wang, J., Zhang, Y., et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0765-8 · Cited by 71
Loss of Mdm4 Results in p53 -Dependent Dilated Cardiomyopathy
Xiong, S., Van Pelt, C. S., Elizondo-Fraire, A. C., Fernandez-Garcia, B., & Lozano, G. (2007) · Circulation · doi:10.1161/circulationaha.107.689901 · Cited by 71
Inactivation of the tumor suppressor p53 by long noncoding RNA RMRP
Chen, Y., Hao, Q., Wang, S., Cao, M., Huang, Y., Weng, X., Wang, J., Zhang, Z., He, X., Lu, H., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2026813118 · Cited by 71
The p53 mutation “gradient effect” and its clinical implications
Zambetti, G. P. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21217 · Cited by 71
Dp1is required for extra-embryonic development
Kohn, M. J., Bronson, R. T., Harlow, E., Dyson, N. J., & Yamasaki, L. (2003) · Development · doi:10.1242/dev.00355 · Cited by 71
DNA repair during organogenesis
Vinson, R. K., & Hales, B. F. (2002) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s0027-5107(02)00223-3 · Cited by 71
p76MDM2 Inhibits the Ability of p90MDM2to Destabilize p53
Perry, M. E., Mendrysa, S. M., Saucedo, L. J., Tannous, P., & Holubar, M. K. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.8.5733 · Cited by 71
DNMT1 represses p53 to maintain progenitor cell survival during pancreatic organogenesisPreprint
Georgia, S. K., Kanji, M., & Bhushan, A. (2013) · Genes & Development · doi:10.1101/gad.207001.112 · Cited by 72
Mdm2, but not Mdm4, protects terminally differentiated smooth muscle cells from p53-mediated caspase-3-independent cell death
Boesten, L. S. M., Zadelaar, S. M., De Clercq, S., Francoz, S., van Nieuwkoop, A., Biessen, E. A. L., Hofmann, F., Feil, S., Feil, R., Jochemsen, A. G., et al. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401973 · Cited by 70
Inhibition of p53 DNA Binding Function by the MDM2 Protein Acidic Domain
Cross, B. L., Chen, L., Cheng, Q., Li, B., Yuan, Z.-M., & Chen, J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.228981 · Cited by 72
Cyclin A-CDK Phosphorylation Regulates MDM2 Protein Interactions
Zhang, T., & Prives, C. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m011326200 · Cited by 70
The E7 Oncoprotein of Human Papillomavirus Type 16 Stabilizes p53 through a Mechanism Independent of p19 ARF
Seavey, S. E., Holubar, M. K., Saucedo, L. J., & Perry, M. E. (1999) · Journal of Virology · doi:10.1128/jvi.73.9.7590-7598.1999 · Cited by 69
Regulation of the p53 Family Proteins by the Ubiquitin Proteasomal Pathway
Bang, S., Kaur, S., & Kurokawa, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010261 · Cited by 69
“MDM2 TAp73α * TAp73β * ∆Np73α ** Embryonically lethal [44,45] Oncogene [46–55] TA Domain [200] SAM Domain [222] 1999 [170–172] *”
BackgroundInfluential
ARF tumor suppression in the nucleolus
Maggi, L. B., Winkeler, C. L., Miceli, A. P., Apicelli, A. J., Brady, S. N., Kuchenreuther, M., & Weber, J. D. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.01.016 · Cited by 73
The long and the short of it: the MDM4 tail so far
Haupt, S., Mejía-Hernández, J. O., Vijayakumaran, R., Keam, S. P., & Haupt, Y. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz007 · Cited by 70
Role of Pirh2 in Mediating the Regulation of p53 and c-Myc
Hakem, A., Bohgaki, M., Lemmers, B., Tai, E., Salmena, L., Matysiak‐Zablocki, E., Jung, Y.-S., Karásková, J., Kaustov, L., Duan, S., et al. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1002360 · Cited by 69
Regulation of p53 and MDM2 Activity by MTBP
Brady, M., Vlatković, N., & Boyd, M. T. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.2.545-553.2005 · Cited by 69
Small Molecule Antagonists of the MDM2 Oncoprotein as Anticancer Agents
Buolamwini, J. K., Addo, J. K., Kamath, S., Patil, S. A., Mason, M., & Ores, M. (2005) · Current Cancer Drug Targets · doi:10.2174/1568009053332672 · Cited by 69
Mdm2 promotes Cdc25C protein degradation and delays cell cycle progression through the G2/M phase
Giono, L. E., Resnick‐Silverman, L., Carvajal, L. A., Clair, S. S., & Manfredi, J. J. (2017) · Oncogene · doi:10.1038/onc.2017.254 · Cited by 68
Regulation of the Mdm2-p53 signaling axis in the DNA damage response and tumorigenesis
Carr, M. I., & Jones, S. N. (2016) · Translational Cancer Research · doi:10.21037/tcr.2016.11.75 · Cited by 71
Self-citation
Stabilization of the MDM2 Oncoprotein by Mutant p53
Peng, Y., Chen, L., Li, C., Lu, W., Agrawal, S., & Chen, J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c000781200 · Cited by 67
The p53 response: Emerging levels of co-factor complexity
Coutts, A. S., & La Thangue, N. B. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.150 · Cited by 72
Germ Cell Apoptosis and DNA Damage Responses
Bailly, A., & Gartner, A. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-4015-4_9 · Cited by 70
Dangerous habits of a security guard: the two faces of p53 as a drug target
Gudkov, A. V., & Komarova, E. A. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm052 · Cited by 67
Zebrafish Models of p53 FunctionsPreprint
Storer, N. Y., & Zon, L. I. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001123 · Cited by 67
Distinct roles of Mdm2 and Mdm4 in red cell production
Maetens, M., Doumont, G., Clercq, S. D., Francoz, S., Froment, P., Bellefroid, E., Klingmuller, U., Lozano, G., & Marine, J.-C. (2007) · Blood · doi:10.1182/blood-2006-03-013656 · Cited by 64
Phosphorylation and Degradation of MdmX Is Inhibited by Wip1 Phosphatase in the DNA Damage Response
Zhang, X., Lin, L., Guo, H., Yang, J., Jones, S. N., Jochemsen, A., & Lu, X. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0634 · Cited by 67
“MEFs were harvested and cultured as previously described (12, 22, 23).”
Self-citation
Regulation of p53 by Mdm2 E3 Ligase Function Is Dispensable in Embryogenesis and Development, but Essential in Response to DNA Damage
Tollini, L. A., Jin, A., Park, J., & Zhang, Y. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.06.006 · Cited by 66
MDM2 inhibition rescues neurogenic and cognitive deficits in a mouse model of fragile X syndrome
Li, Y., Stockton, M. E., Bhuiyan, I., Eisinger, B. E., Gao, Y., Miller, J. L., Bhattacharyya, A., & Zhao, X. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad9370 · Cited by 66
HIPK2 neutralizes MDM2 inhibition rescuing p53 transcriptional activity and apoptotic function
Stefano, V. D., Blandino, G., Sacchi, A., Soddu, S., & D’Orazi, G. (2004) · Oncogene · doi:10.1038/sj.onc.1207656 · Cited by 67
Activation of an MDM2-specific Caspase by p53 in the Absence of Apoptosis
Pochampally, R. R., Fodera, B., Chen, L., Lu, W., & Chen, J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.21.15271 · Cited by 66
Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them?
Hároníková, L., Bonczek, O., Zatloukalová, P., Kokas, F. Z., Kucerikova, M., Coates, P. J., Fåhræus, R., & Vojtěšek, B. (2021) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-021-00293-6 · Cited by 72
It’s Getting Complicated—A Fresh Look at p53-MDM2-ARF Triangle in Tumorigenesis and Cancer Therapy
Kung, C.-P., & Weber, J. D. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.818744 · Cited by 71
Dendrimers as prospective nanocarrier for targeted delivery against lung cancer
Arora, V., Abourehab, M. A. S., Modi, G. P., & Kesharwani, P. (2022) · European Polymer Journal · doi:10.1016/j.eurpolymj.2022.111635 · Cited by 66
Wild type p53 reactivation: From lab bench to clinic
Selivanova, G. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.03.049 · Cited by 68
Emerging Non-Canonical Functions and Regulation by p53: p53 and Stemness
Olivos, D. J., & Mayo, L. D. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17121982 · Cited by 67
Differential p53-Independent Outcomes of p19 Arf Loss in Oncogenesis
Chen, Z., Carracedo, A., Lin, H., Koutcher, J. A., Behrendt, N., Egia, A., Alimonti, A., Carver, B. S., Gerald, W. L., Teruya‐Feldstein, J., et al. (2009) · Science Signaling · doi:10.1126/scisignal.2000053 · Cited by 66
Initial testing of the MDM2 inhibitor RG7112 by the pediatric preclinical testing program
Carol, H., Reynolds, C. P., Kang, M. H., Keir, S. T., Maris, J. M., Gorlick, R. G., Kolb, E. A., Billups, C. A., Geier, B., Kurmasheva, R. T., et al. (2012) · Pediatric Blood & Cancer · doi:10.1002/pbc.24235 · Cited by 64
The Many Faces of MDM2 Binding Partners
Riley, M. F., & Lozano, G. (2012) · Genes & Cancer · doi:10.1177/1947601912455322 · Cited by 66
Ribosomal protein S27-like is a physiological regulator of p53 that suppresses genomic instability and tumorigenesis
Xiong, X., Zhao, Y., Tang, F., Wei, D., Thomas, D. G., Wang, X., Liu, Y., Zheng, P., & Sun, Y. (2014) · eLife · doi:10.7554/elife.02236 · Cited by 66
Mouse models to study the interaction of risk factors for human liver cancer.
Sell, S. (2003) · PubMed · Cited by 64
Identification of a Sequence Element from p53 That Signals for Mdm2-Targeted Degradation
Gu, J., Chen, D., Lichtenstein, J. H. R., Rubin, R. M., & Yuan, Z.-M. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.4.1243-1253.2000 · Cited by 64
Design, synthesis, and biological evaluation of nitroisoxazole-containing spiro[pyrrolidin-oxindole] derivatives as novel glutathione peroxidase 4/mouse double minute 2 dual inhibitors that inhibit breast adenocarcinoma cell proliferation
Liu, S., Zhao, Q., Peng, C. Y., Mao, Q., Wu, F., Zhang, F., Feng, Q., He, G., & Han, B. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113359 · Cited by 66
Cyclin-Dependent Kinase 5 Regulates PSD-95 Ubiquitination in Neurons
Bianchetta, M. J., Lam, T. T., Jones, S. N., & Morabito, M. A. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.2388-11.2011 · Cited by 63
Self-citation
Murine Double Minute-2 Prevents p53-Overactivation-Related Cell Death (Podoptosis) of Podocytes
Thomasová, D., Bruns, H., Kretschmer, V., Ebrahim, M., Romoli, S., Liapis, H., Kotb, A. M., Endlich, N., & Anders, H. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014040345 · Cited by 64
A novel flexible framework with automatic feature correspondence optimization for nonrigid registration in radiotherapy
Osorio, E. M. V., Hoogeman, M. S., Bondar, L., Levendag, P. C., & Heijmen, B. J. M. (2009) · Medical Physics · doi:10.1118/1.3134242 · Cited by 62
Switch from p53 to MDM2 as differentiating human keratinocytes lose their proliferative potential and increase in cellular size
Dazard, J.-E., Piette, J., Basset‐Séguin, N., Blanchard, J., & Gandarillas, A. (2000) · Oncogene · doi:10.1038/sj.onc.1203695 · Cited by 62
Control of Human PIRH2 Protein Stability
Logan, I. R., Sapountzi, V., Gaughan, L., Neal, D. E., & Robson, C. N. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312712200 · Cited by 62
Negative Regulation of p53 Functions by Daxx and the Involvement of MDM2
Zhao, L., Liu, J., Sidhu, G. S., Niu, Y., Liu, Y., Wang, R., & Liao, D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406743200 · Cited by 61
p53 in the CNS: Perspectives on Development, Stem Cells, and Cancer
Mendrysa, S. M., Ghassemifar, S., & Malek, R. A. (2011) · Genes & Cancer · doi:10.1177/1947601911409736 · Cited by 65
The p53–Mdm2 network in progenitor cell expansion during mouse postnatal development
Liu, G., Terzian, T., Xiong, S., Pelt, C. S. V., Audiffred, A., Box, N. F., & Lozano, G. (2007) · The Journal of Pathology · doi:10.1002/path.2238 · Cited by 62
Chemotherapy induces NEDP1-mediated destabilization of MDM2
Watson, I. R., Li, B. K., Roche, O., Blanch, A., Ohh, M., & Irwin, M. S. (2009) · Oncogene · doi:10.1038/onc.2009.314 · Cited by 60
HDM2 phosphorylation by MAPKAP kinase 2
Weber, H. O., Ludwig, R. L., Morrison, D. K., Kotlyarov, A., Gaestel, M., & Vousden, K. H. (2005) · Oncogene · doi:10.1038/sj.onc.1208389 · Cited by 60
MDM2 promotes SUMO-2/3 modification of p53 to modulate transcriptional activity
Stindt, M., Carter, S. A., Vigneron, A. M., Ryan, K. M., & Vousden, K. H. (2011) · Cell Cycle · doi:10.4161/cc.10.18.17436 · Cited by 62
Making sense of ubiquitin ligases that regulate p53
Jain, A. K., & Barton, M. C. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.7.13445 · Cited by 60
NF-κB inhibits T-cell activation-induced, p73-dependent cell death by induction of MDM2
Busuttil, V., Droin, N. M., McCormick, L. L., Bernassola, F., Candi, E., Melino, G., & Green, D. R. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006163107 · Cited by 59
Mdm2 Is Required for Survival and Growth of p53-Deficient Cancer Cells
Feeley, K. P., Adams, C. M., Mitra, R., & Eischen, C. M. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0809 · Cited by 57
Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies
Koblish, H. K., Li, Y., Shin, N., Hall, L. M., Wang, Q., Wang, K., Covington, M. B., Marando, C. A., Bowman, K., Boer, J., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0199108 · Cited by 59
The intestinal epithelium compensates for p53-mediated cell death and guarantees organismal survival
Valentin-Vega, Y. A., Okano, H., & Lozano, G. (2008) · Cell Death & Differentiation · doi:10.1038/cdd.2008.109 · Cited by 58
UBE4B, a ubiquitin chain assembly factor, is required for MDM2-mediated p53 polyubiquitination and degradation
Wu, H., & Leng, R. P. (2011) · Cell Cycle · doi:10.4161/cc.10.12.15882 · Cited by 59
Cell Cycle Arrest and Cell Death Are Controlled by p53-dependent and p53-independent Mechanisms in Tsg101-deficient Cells
Carstens, M. J., Krempler, A., Triplett, A. A., van Lohuizen, M., & Wagner, K. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m400408200 · Cited by 58
Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop
Arriola, E. L., Lopez, A. R., & Chresta, C. M. (1999) · Oncogene · doi:10.1038/sj.onc.1202391 · Cited by 58
Tied Up in Loops: Positive and Negative Autoregulation of p53Preprint
Lü, X. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000984 · Cited by 58
MdmX Promotes Bipolar Mitosis To Suppress Transformation and Tumorigenesis in p53-Deficient Cells and Mice
Matijasevic, Z., Steinman, H. A., Hoover, K., & Jones, S. N. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01108-07 · Cited by 58
“The developmental block imposed by the loss of Mdm2 or MdmX can be relieved by the deletion of p53 (9, 21, 28, 30, 32) or by Mdm2 amplification (20, 22) or, in the case of MdmX, partially rescued by the deletion of the p53 downstream effector p21 (43).”
BackgroundSelf-citation

Authors: Jones, S. N., Roe, A. E., Donehower, L. A., & Bradley, A.
Affiliations: Howard Hughes Medical Institute (US)
Baylor College of Medicine (US)
ORCID: Bradley, Allan
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 1995-11
Volume: 378
Issue: 6553
Pages: 206-208
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/378206a0
OpenAlex: W1993864973
Semantic Scholar: efc84bf5f5d1747443a3eb4555f9b5ede31b368f
Cited by: 1,280
References: 24
Citations by year: 2026: 9 · 2025: 17 · 2024: 30 · 2023: 31 · 2022: 28 · 2021: 35 · 2020: 41 · 2019: 28 · 2018: 31 · 2017: 38 · 2016: 54 · 2015: 34 · 2014: 59 · 2013: 30 · 2012: 60
FWCI: 14.50
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Developmental Biology and Gene Regulation
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
Keywords: MDM2, p53, embryonic lethality, developmental regulation, tumor suppressor, sarcoma, leukemia
MeSH terms: Proto-Oncogene Mas, Animals, Base Sequence, Cell Cycle, Cell Line, Crosses, Genetic, Female, Embryonic and Fetal Development, Genes, Lethal, Molecular Sequence Data, Mutation, Nuclear Proteins, Proto-Oncogene Proteins, Tumor Suppressor Protein p53, 3T3 Cells, DNA Primers, Gene Targeting, Mice, Proto-Oncogene Proteins c-mdm2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks